Navigation Links
AEterna Zentaris Announces Changes to its Management Team
Date:4/11/2008

ent to explore other such opportunities with a view to identifying additional non-core assets as a further potential source of non-dilutive funding.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.
News releases and additional information are available at http://www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... GLASGOW, Scotland , September 17, 2014 ... a new mode of action from a ... a decade  MGB Biopharma, a ... of anti-infectives, announces today that it has ... of its lead antibacterial, MGB-BP-3, against a ...
(Date:9/16/2014)... Washington, USA (PRWEB) September 16, 2014 ... to create the features that we desire in optical ... Center at Montana State University. “As we explore surfaces ... Some of those lessons were presented in San Diego ... of Light: Light in Nature ” chaired by Shaw ...
(Date:9/16/2014)... 16, 2014 --The emerging field of molecular electronics ... next level, enabling the construction of tiny circuits ... individual molecules would take on the roles currently ... A team of researchers from five Japanese and ... use in small-scale electronics: a molecule called picene. ...
(Date:9/16/2014)... HILL, N.C. , Sept. 16, 2014 ... experimental heart failure compound has been shown to be ... preclinical results demonstrate an alternative to intravenous infusions that ... HNO prodrugs. The data were presented yesterday at the ... Annual Scientific Meeting in Las Vegas ...
Breaking Biology Technology:MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5The future face of molecular electronics 2Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2
... a leading global,full-service contract research organization, announced it ... Clinical Pharmacology., Dr. Wei joins Medpace with ... early phase cardio-metabolic studies. He will consult,with sponsors ... to which studies merit inclusion in the programs ...
... today announced that it has appointed Mr. Jorge,Cantonnet to ... effective as of 1 February 2008. Mr. Cantonnet is ... agro-biotechnology company listed on OTCBB in Dec 2007,(OTC Bulletin ... million in fiscal year ended 30 September 2007, with ...
... and SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ - MIGENIX ... drugs for infectious,diseases, will add a 600mg celgosivir ... viral kinetics study in hepatitis C virus,("HCV") treatment-naive ... Health Canada and Institutional Review Board (IRB) approvals. ...
Cached Biology Technology:Medpace Hires Clinical Pharmacologist, Jim Wei, MD, PhD 2China Agro-Technology Appoints New CEO 2China Agro-Technology Appoints New CEO 3MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 2MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 3MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 4MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 5MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 6
(Date:9/16/2014)... Columbia Center for Children,s Environmental Health at the Mailman ... an association between childhood asthma and prenatal exposure to ... products. Results appear online in the journal Environmental ... exposed during pregnancy to higher levels of the chemicals, ... 72 percent and 78 percent increase in risk of ...
(Date:9/16/2014)... 17, 2014)The North American Menopause Society (NAMS) has ... care of midlife womenon everything from hot flashes ... American Menopause Society Recommendations for Clinical Care of ... Society,s journal Menopause . This is the ... care of midlife women freely available to all ...
(Date:9/16/2014)... "molecular brakes" that time the generation of important cells ... cells" translate sound waves into electrical signals that are ... If the arrangement of the cells is disordered, hearing ... will be published in The Journal of Neuroscience ... Hey2 act as brakes to prevent hair cell generation ...
Breaking Biology News(10 mins):Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2
... Suppressing a cellular cleanup-mechanism known as autophagy can ... neural degeneration. In an upcoming issue of Autophagy, scientists ... the first time that the opposite is true as ... flies prevented the age-dependent accumulation of cellular damage in ...
... lifeless lakeshore lapped by waves, floating algae learned to survive ... the Earth into a green paradise. The secrets of ... to the sequencing of a modern descendent of these first ... on recently exposed shorelines, quickly fruits, and then dies. ...
... collection of genes the genome of a ... link between single-celled algae and flowering plants. Just ... understand human genomic history, the sequencing of plant genomes ... kingdom, according to Ralph S. Quatrano, Ph.D., the Spencer ...
Cached Biology News:Aging gracefully requires taking out the trash 2Aging gracefully requires taking out the trash 3Moss genome shows how plants invaded the land and learned to survive heat and drought 2Moss genome shows how plants invaded the land and learned to survive heat and drought 3WUSTL researchers spearhead key genome initiative 2WUSTL researchers spearhead key genome initiative 3WUSTL researchers spearhead key genome initiative 4
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
SHEEP ANTI FLECAINIDE...
ANTI PIG LDH H4...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
Biology Products: